denkapparat Operations GmbH Takes $341,000 Position in Incyte Co. (NASDAQ:INCY)

denkapparat Operations GmbH bought a new position in Incyte Co. (NASDAQ:INCY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,936 shares of the biopharmaceutical company’s stock, valued at approximately $341,000.

A number of other large investors have also recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new stake in Incyte in the third quarter worth about $156,611,000. Norges Bank bought a new stake in shares of Incyte during the fourth quarter worth $121,890,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Incyte by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,643,067 shares of the biopharmaceutical company’s stock valued at $113,487,000 after purchasing an additional 33,847 shares during the period. Pictet Asset Management Holding SA grew its holdings in shares of Incyte by 73.4% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,313,873 shares of the biopharmaceutical company’s stock worth $90,749,000 after purchasing an additional 556,218 shares during the last quarter. Finally, Sound Shore Management Inc. CT increased its stake in Incyte by 98.4% in the 4th quarter. Sound Shore Management Inc. CT now owns 1,201,089 shares of the biopharmaceutical company’s stock worth $82,959,000 after buying an additional 595,741 shares during the period. 96.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on INCY. Morgan Stanley dropped their target price on shares of Incyte from $69.00 to $65.00 and set an “equal weight” rating on the stock in a research note on Monday. Royal Bank of Canada reduced their price objective on Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a report on Friday, January 10th. William Blair downgraded Incyte from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 18th. Finally, Wells Fargo & Company lifted their price objective on Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Incyte has an average rating of “Hold” and an average price target of $74.88.

Incyte Stock Down 0.9 %

NASDAQ:INCY opened at $60.68 on Friday. The company’s 50 day moving average is $69.76 and its two-hundred day moving average is $70.05. The company has a market cap of $11.74 billion, a PE ratio of 224.75, a P/E/G ratio of 0.41 and a beta of 0.76. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. Analysts anticipate that Incyte Co. will post 4.86 EPS for the current year.

Insider Transactions at Incyte

In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of Incyte stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the completion of the sale, the executive vice president now directly owns 25,848 shares in the company, valued at approximately $1,914,561.36. The trade was a 35.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the sale, the executive vice president now owns 33,567 shares in the company, valued at $2,272,150.23. The trade was a 37.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 46,827 shares of company stock worth $3,322,618 over the last three months. 17.60% of the stock is currently owned by insiders.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.